Compare Abbott Laboratories (ABT) vs ThredUp Inc (TDUP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs ThredUp Inc — how do they compare? Abbott Laboratories trades at $95.36 (market cap $166.94B), while ThredUp Inc trades at $6.29 (market cap $882.64M). The key difference: Abbott Laboratories is far larger — about 189.1× ThredUp Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while ThredUp Inc pays none. Which is the better fit depends on your goals.
| ABT | TDUP | |
|---|---|---|
Market Cap | $166.94B | $882.64M |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $12.08 |
52-Week Low | $82.57 | $3.11 |
Enterprise Value | $193.69B | $885.37M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
TDUP trades at $6.84, down 2.7% today, with a consensus price target of $6.90. The stock shows bullish technical signals from moving averages, though oscillators are neutral. Recent Q1 2026 results met EPS expectations with record active buyers and 15% revenue growth. The company maintains a high gross margin of 79.4% but continues to report net losses, with improving cash flow from operations turning positive in 2025.
Investment outlook remains cautiously optimistic given analyst consensus (57% buy ratings) and recent business initiatives including AI integration and marketplace expansion. Key risks include persistent unprofitability and competitive pressures in resale markets. The stock presents potential for growth if margin improvements continue, but requires monitoring of earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
